Research map: Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates

Back to the article

Papers in this map

  1. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease · Clifford R. Jack · 2018 · 10916 citations · Cited by this paper
  2. Advancements in longevity pharmacology research – are we finally seeing clinical progression? · 2026 · Related
  3. Alzheimer's Disease: The Amyloid Cascade Hypothesis · John Hardy · 1992 · 7593 citations · Cited by this paper
  4. Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · 2025 · Related
  5. Donanemab in Early Symptomatic Alzheimer Disease · John Randall Sims · 2023 · 2897 citations · Cited by this paper
  6. Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · 2025 · Related
  7. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup · Clifford R. Jack · 2024 · 2682 citations · Cited by this paper
  8. The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · 2026 · Related
  9. Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature · Peter T. Nelson · 2012 · 2145 citations · Cited by this paper
  10. Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · 2025 · Related
  11. How were new medicines discovered? · David C. Swinney · 2011 · 1843 citations · Cited by this paper
  12. Menin inhibitors for adult acute myeloid leukemia: 2025 update · 2025 · Related
  13. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein · Roussoudan Bourtchuladze · 1994 · 1817 citations · Cited by this paper
  14. Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · 2026 · Related
  15. Donanemab in Early Alzheimer’s Disease · Mark A. Mintun · 2021 · 1779 citations · Cited by this paper
  16. Hypertension and Alzheimer's disease: Pathological interplay, comorbidity risks, and new strategies for synergistic management · 2025 · Related
  17. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? · Eric van Steen · 2005 · 1707 citations · Cited by this paper
  18. Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · 2026 · Related
  19. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease · Patrick L. McGeer · 1996 · 1370 citations · Cited by this paper
  20. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease · 2026 · Related
  21. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment · Suzanne Craft · 2011 · 1256 citations · Cited by this paper
  22. Effects of cAMP Simulate a Late Stage of LTP in Hippocampal CA1 Neurons · Uwe Frey · 1993 · 1233 citations · Cited by this paper
  23. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression · Xinyi Wang · 2019 · 1164 citations · Cited by this paper
  24. Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed · Suzanne M. de la Monte · 2008 · 1163 citations · Cited by this paper
  25. Biomarkers for Alzheimer's disease: current status and prospects for the future · Kaj Blennow · 2018 · 1034 citations · Cited by this paper
  26. Memantine for dementia · Rupert H. McShane · 2006 · 1025 citations · Cited by this paper
  27. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future · Yun Zhang · 2023 · 957 citations · Cited by this paper
  28. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease · HEIDI S. PHILLIPS · 1991 · 932 citations · Cited by this paper
  29. Intranasal insulin improves cognition and modulates β-amyloid in early AD · Mark A. Reger · 2007 · 837 citations · Cited by this paper
  30. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease · Alexandre Bejanin · 2017 · 831 citations · Cited by this paper
  31. A “mitochondrial cascade hypothesis” for sporadic Alzheimer's disease · Russell Howard Swerdlow · 2004 · 758 citations · Cited by this paper
  32. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease · Lutz Frölich · 1998 · 753 citations · Cited by this paper
  33. p38MAPK: stress responses from molecular mechanisms to therapeutics · Lydia Coulthard · 2009 · 720 citations · Cited by this paper
  34. Precursor form of brain‐derived neurotrophic factor and mature brain‐derived neurotrophic factor are decreased in the pre‐clinical stages of Alzheimer's disease · Shiyong Peng · 2005 · 706 citations · Cited by this paper
  35. Intranasal insulin improves memory in humans · Christian Benedict · 2004 · 696 citations · Cited by this paper
  36. dunce, a mutant of Drosophila deficient in learning. · Yadin Dudai · 1976 · 634 citations · Cited by this paper
  37. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine · Michael J. Owens · 2001 · 521 citations · Cited by this paper
  38. Regulation of Neurogenesis in Adult Mouse Hippocampus by cAMP and the cAMP Response Element-Binding Protein · Shin Nakagawa · 2002 · 495 citations · Cited by this paper
  39. High Cortisol and the Risk of Dementia and Alzheimer’s Disease: A Review of the Literature · Sami Ouanes · 2019 · 481 citations · Cited by this paper

Source: OpenAlex (CC0)